FR19C1030I1 - DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES - Google Patents

DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES

Info

Publication number
FR19C1030I1
FR19C1030I1 FR19C1030C FR19C1030C FR19C1030I1 FR 19C1030 I1 FR19C1030 I1 FR 19C1030I1 FR 19C1030 C FR19C1030 C FR 19C1030C FR 19C1030 C FR19C1030 C FR 19C1030C FR 19C1030 I1 FR19C1030 I1 FR 19C1030I1
Authority
FR
France
Prior art keywords
delivery system
drug delivery
water soluble
active substances
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1030C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardenia Investments Ltd
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of FR19C1030I1 publication Critical patent/FR19C1030I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
FR19C1030C 2007-12-19 2019-05-06 DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES Active FR19C1030I1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
PCT/SE2008/051515 WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (1)

Publication Number Publication Date
FR19C1030I1 true FR19C1030I1 (en) 2019-06-21

Family

ID=40795732

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1030C Active FR19C1030I1 (en) 2007-12-19 2019-05-06 DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES

Country Status (26)

Country Link
US (4) US8999382B2 (en)
EP (1) EP2231189B1 (en)
JP (1) JP5466172B2 (en)
KR (1) KR101572703B1 (en)
CN (1) CN101951956B (en)
AU (1) AU2008339099B2 (en)
BR (1) BRPI0821740B1 (en)
CA (1) CA2709266C (en)
CY (2) CY1119805T1 (en)
DK (1) DK2231189T3 (en)
EA (1) EA015247B1 (en)
ES (1) ES2650242T3 (en)
FR (1) FR19C1030I1 (en)
HR (1) HRP20171796T1 (en)
HU (1) HUE034684T2 (en)
LT (2) LT2231189T (en)
MX (1) MX2010006914A (en)
MY (2) MY157187A (en)
NL (1) NL300987I9 (en)
NO (2) NO2231189T3 (en)
NZ (1) NZ586859A (en)
PL (1) PL2231189T3 (en)
PT (1) PT2231189T (en)
SI (1) SI2231189T1 (en)
WO (2) WO2009078754A1 (en)
ZA (1) ZA201004685B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EA201101530A1 (en) * 2009-04-21 2012-03-30 Селекта Байосайенсиз, Инк. IMMUNONANOTHERAPY, PROVIDING TH1-DISPERSED RESPONSE
CN105194665A (en) 2010-05-26 2015-12-30 西莱克塔生物科技公司 Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (en) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. MODIFIED NICOTINE COMPOUNDS AND RELATED METHODS
CN103908432B (en) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 A kind of freeze-dried composition and preparation method thereof of Ipsapirone albumin
CN112239418B (en) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 Preparation method of retinol compound and sodium salt thereof
CN112321465B (en) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 Phenyl-containing compound, intermediate thereof, preparation method and application
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (en) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Use of fumaric acid derivatives in transplant medicine
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (en) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
AU2002347747A1 (en) * 2002-07-23 2004-02-09 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
SE0202311D0 (en) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (en) 2003-09-04 2006-08-03 Nano Career Kk Composition containing nanoparticle containing water-soluble basic medicine encapsulated therein
US20050196343A1 (en) 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
WO2007027941A2 (en) * 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078755A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Also Published As

Publication number Publication date
EA015247B1 (en) 2011-06-30
BRPI0821740A2 (en) 2020-02-27
US20150164819A1 (en) 2015-06-18
EA200802350A2 (en) 2009-06-30
AU2008339099A1 (en) 2009-06-25
USRE49741E1 (en) 2023-12-05
PL2231189T3 (en) 2018-03-30
SI2231189T1 (en) 2018-03-30
JP2011507838A (en) 2011-03-10
ES2650242T3 (en) 2018-01-17
NO2019023I1 (en) 2019-05-08
EP2231189A4 (en) 2013-10-09
CY2019021I2 (en) 2019-11-27
BRPI0821740B1 (en) 2021-05-18
AU2008339099B2 (en) 2015-08-13
DK2231189T3 (en) 2017-12-11
ZA201004685B (en) 2011-03-30
USRE49742E1 (en) 2023-12-05
PT2231189T (en) 2017-12-12
US9993438B2 (en) 2018-06-12
MY157186A (en) 2016-05-13
LT2231189T (en) 2017-12-27
KR20100094575A (en) 2010-08-26
NL300987I2 (en) 2019-05-09
EP2231189A1 (en) 2010-09-29
US8999382B2 (en) 2015-04-07
JP5466172B2 (en) 2014-04-09
MY157187A (en) 2016-05-13
US20110014281A1 (en) 2011-01-20
KR101572703B1 (en) 2015-11-27
CY2019021I1 (en) 2019-11-27
LTPA2019508I1 (en) 2019-05-10
NO2231189T3 (en) 2018-02-03
CN101951956B (en) 2012-10-17
HRP20171796T1 (en) 2018-01-26
NZ586859A (en) 2012-06-29
EA200802350A3 (en) 2009-10-30
WO2009078802A1 (en) 2009-06-25
MX2010006914A (en) 2010-11-10
CN101951956A (en) 2011-01-19
HUE034684T2 (en) 2018-02-28
EP2231189B1 (en) 2017-09-06
NL300987I9 (en) 2019-05-16
CA2709266A1 (en) 2009-06-25
CY1119805T1 (en) 2018-06-27
CA2709266C (en) 2017-09-26
WO2009078754A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
FR19C1030I1 (en) DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES
FR17C1027I2 (en) USEFUL LIPOSOMES FOR DRUG DELIVERY
MX2020011961A (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances.
WO2009088414A3 (en) Oral pharmaceutical dosage forms
EP2056792A4 (en) Drug delivery systems comprising solid solutions of weakly basic drugs
IL202614A0 (en) Intravaginal drug delivery devices for the delivery of macromolecules and water soluble drugs
PL2063861T3 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
IL218165A (en) Highly concentrated stable pharmaceutical formulations for subcutaneous administration of a pharmaceutically active anti-cd20 antibody
RS55705B1 (en) Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition
BRPI0818129A2 (en) Safe drug delivery and administration system
IL196394A0 (en) Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex
IL227898A (en) Drug delivery system with a small amount of a therapeutic agent
ZA200610770B (en) Dosage form for delivery of multiple drug forms
EP2023900A4 (en) Controlled dose drug delivery system
HRP20181517T1 (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EP1983930A4 (en) Drug delivery system for retarding release of water soluble drugs
WO2006060325A3 (en) Coated drug delivery formulations
FR2912915B1 (en) FAST DISINTEGRATING FILM FOR THE ORAL ADMINISTRATION OF ACTIVE SUBSTANCES.
EP2231192A4 (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EP2012705A4 (en) Pharmaceutical formulations for iontophoretic drug delivery
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
FR2978046B1 (en) PHARMACEUTICAL DOSAGE FORMS OF INTRATHECAL BACLOFEN AND ADMINISTRATION SYSTEM THEREFOR
ZA200802187B (en) Drug delivery system for topical administration
ZA200901366B (en) Drug delivery systems comprising solid solutions of weakly basic drugs
FR2904225B1 (en) PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULTY OF THE ROUTE OF ADMINISTRATION TO WHICH THEY ARE INTENDED